Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL)

Experimental Hematology

Volumn 37, Issue 2, 2009, Pages

  Cycon, Kelly A ^a   Rimsza, Lisa M ^b   Murphy, Shawn P ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQ ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 TRANSCRIPTIONAL ACTIVATOR CLASS 2 TRANSACTIVATOR; PROTEIN; RFX PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; BETA CHAIN; CELL SURFACE; CHROMOSOME 6; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 58149194592     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.10.001     Document Type: Article

References (38)

1. Rosenwald A., Wright G., Chan W., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
2. Alizadeh A., Eisen M., Davis R., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
3. Rimsza L., Roberts R., Miller T., et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103 (2004) 4251-4258
4. Roberts R.A., Wright G., Rosenwald A.R., et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 108 (2006) 311-318
5. Rimsza L., Farinha P., Fuchs D., Masoud H., Connors J., and Gascoyne R. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leukemia Lymphoma 48 (2007) 542-546
6. Rimsza L.M., Roberts R.A., Campo E., et al. Loss of major histocompatibility class II expression in non-immune privileged site diffuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 107 (2006) 1101-1107
7. Stopeck A.T., Gessner A., Miller T.P., et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 6 (2000) 3904-3909
8. Lippman S.M., Spier C.M., Miller T.P., Slymen D.J., Rybski J.A., and Grogan T.M. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 3 (1990) 361-367
9. List A.F., Spier C., Greer J., et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11 (1993) 1652-1660
10. Medeiros L.J., Picker L.J., Gelb A.B., et al. Numbers of host "helper" T cells and proliferating cells predict survival in diffuse small-cell lymphoma. J Clin Oncol 7 (1989) 1009-1017
11. Glimcher L., and Kara C. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 10 (1992) 13-49
12. Mach B., Steimle V., Martinez-Soria E., and Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 14 (1996) 301-331
13. Waldburger J.-M., Masternak K., Muhlethaler-Mottet A., et al. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol Rev 178 (2000) 148-165
14. Harton J.A., and Ting J.P. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 20 (2000) 6185-6194
15. Silacci P., Mottet A., Steimle V., Reith W., and Mach B. Developmental extinction of major histocompatibility complex class II gene expression in plasmacytes is mediated by silencing of the transactivator gene CIITA. J Exp Med 180 (1994) 1329-1336
16. Riemersma S., Jordanova E., Schop R., et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96 (2000) 3569-3577
17. Jordanova E.S., Phillippo K., Giphart M.J., Schuuring E., and Kluin P.M. Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics 55 (2003) 203-209
18. Roberts R.A., Miller T.P., and Rimsza L.M. Loss of major histocompatibility class II (MHCII) gene expression in diffuse large B cell lymphoma (DLBCL) is not generally due to genetic mutations in the coding regions of CIITA or RFX. Blood 108 (2007) 578a
19. Holtz R., Choi J.C., Petroff M.G., Piskurich J.F., and Murphy S.P. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts. Biol Reprod 69 (2003) 915-924
20. Choi J., Petroff M., Holtz R., Alfaidy N., and Murphy S. Dampening of IFN-g-inducible gene expression in human choriocarcinoma cells is due to phosphatase-mediated inhibition of the JAK/STAT-1 pathway. J Immunol 178 (2007) 1598-1607
21. Beck S., and Trowsdale J. Sequence organization of the class II region of the human MHC. Immuno Rev 167 (1999) 201-210
22. Aguado B., Bahram S., Beck S., et al. Complete sequence and gene map of a human major histocompatibility complex. Nature 401 (1999) 921-923
23. Seliger B., Wollscheid U., Momburg F., Blankenstein T., and Huber C. Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 56 (2000) 327-336
24. Wolf H., Hauber I., Gulle H., et al. Twin boys with major histocompatibility complex class II deficiency but inducible immune responses. N Engl J Med 332 (1995) 86-90
25. Lennon-Dume'nil A.-M., Barbouche M.-R., Vedrenne J., et al. Uncoordinated HLA-D gene expression in a RFXANK-defective patient with MHC class II deficiency. J Immunol 166 (2001) 5681-5687
26. Nekrep N., Jabrane-Ferrat N., Wolf H., Eibl M., Geyer M., and Peterlin B. Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome. Nat Immunol 11 (2002) 1075-1081
27. Nagarajan U., Louis-Plence P., Desandro A., Nilsen R., Bushey A., and Boss J. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome a MHC class II immunodeficiency. Immunity 10 (1999) 153-162
28. Masternak K., Barras E., Zufferey M., et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 20 (1998) 273-277
29. Prod'homme T., Drenou B., de Ruyffelaere C., et al. Defective class II transactivator expression in a B lymphoma cell line. Leukemia 18 (2004) 832-840
30. Piskurich J.F., Lin K.-I., Lin Y., Wang Y., Ting J.P.-Y., and Calame K. BLIMP-1 mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol 1 (2000) 526-532
31. Ghosh N., Gyory I., Wright G., Wood J., and Wright K.L. Positive regulatory domain I binding factor I silences class II transactivator expression in multiple myeloma cells. J Biol Chem 276 (2001) 15264-15268
32. Tooze R., Stephenson S., and Doody G. Repression of IFN-g Induction of class II transactivator: A role for PRDM1/Blimp-1 in regulation of cytokine signaling. J Immunol 177 (2006) 4584-4593
33. Chen H., Gilbert C.A., Hudson J.A., Bolick S.C., Wright K.L., and Piskurich J.F. Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter. Mol Immunol 44 (2007) 1461-1470
34. Tam W., Gomez M., Chadburn A., Lee J., Chan W., and Knowles D. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphoma. Blood 107 (2006) 4090-4100
35. Green M.R., Yoon H., and Boss J.M. Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility. J Immunol 177 (2006) 3865-3873
36. Murphy S.P., Holtz R., Lewandowski N., Tomasi T.B., and Fuji H. DNA alkylating agents alleviate silencing of CIITA gene expression in L1210 lymphoma cells. J Immunol 169 (2002) 3085-3093
37. Morimoto Y., Toyota M., Satoh A., et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-g in hematopoietic tumour cells. Br J Cancer 90 (2004) 844-852
38. Holling T.M., Schooten E., Langerak A.W., and van den Elsen P.J. Regulation of MHC class II expression in human T-cell malignancies. Blood 103 (2004) 1438-1444